Download MendeleyDiscovery and Pharmacological Characterization of Novel Quinazoline-Based PI3K Delta-Selective Inhibitors.
Hoegenauer, K., Soldermann, N., Stauffer, F., Furet, P., Graveleau, N., Smith, A.B., Hebach, C., Hollingworth, G.J., Lewis, I., Gutmann, S., Rummel, G., Knapp, M., Wolf, R.M., Blanz, J., Feifel, R., Burkhart, C., Zecri, F.(2016) ACS Med Chem Lett 7: 762-767
- PubMed: 27563400
- DOI: https://doi.org/10.1021/acsmedchemlett.6b00119
- Primary Citation of Related Structures:
5IS5, 5ITD - PubMed Abstract:
Inhibition of the lipid kinase PI3Kδ is a promising principle to treat B and T cell driven inflammatory diseases. Using a scaffold deconstruction-reconstruction strategy, we identified 4-aryl quinazolines that were optimized into potent PI3Kδ isoform selective analogues with good pharmacokinetic properties. With compound 11, we illustrate that biochemical PI3Kδ inhibition translates into modulation of isoform-dependent immune cell function (human, rat, and mouse). After oral administration of compound 11 to rats, proximal PD markers are inhibited, and dose-dependent efficacy in a mechanistic plaque forming cell assay could be demonstrated.
Organizational Affiliation:
Global Discovery Chemistry, Center for Proteomic Chemistry, Metabolism and Pharmacokinetics, Autoimmunity, Transplantation and Inflammation, Novartis Institutes for BioMedical Research , Novartis Campus, CH-4002 Basel, Switzerland.
